How Will Novel Agents Impact The HIV Market?
ViiV and Merck are looking to novel mechanisms of action as an opportunity to make up ground on HIV leader Gilead, which has de-emphasized early virology research.
You may also be interested in...
The first HIV single-tablet regimen anchored by a protease inhibitor, Symtuza’s prospects are challenged by competitors already on the market and treatment guidelines that prefer integrase inhibitor regimens.
The company's monoclonal antibody for multidrug resistant HIV-1 patients licensed from TaiMed will launch soon.
Proof-of-concept trialing will soon begin for Janssen's promising HIV-1 prophylactic vaccine, with backing from the Gates Foundation and the NIH.